Related Experiment Videos
Chemoembolization for hepatocellular carcinoma: where does the truth lie?
1Division of Interventional Radiology, The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Blalock 545, 600 North Wolfe Street, Baltimore, Maryland 21287, USA. jfg@jhmi.edu
Journal of Vascular and Interventional Radiology : JVIR
|October 25, 2002
Summary
Hepatocellular carcinoma (HCC) is a lethal cancer with limited treatments. New trials clarify the role of transcatheter arterial chemoembolization (TACE) in managing unresectable HCC, offering insights into its palliative effectiveness.
Area of Science:
- Hepatology and oncology
- Cancer research and treatment
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally, particularly in Asia and Africa.
- Rising incidence in the US is linked to hepatitis C virus (HCV) infection.
- Effective curative options like surgery and transplantation are limited to early-stage HCC.
Discussion:
- Transcatheter arterial chemoembolization (TACE) is a common palliative treatment for unresectable HCC.
- Controversy exists regarding TACE's survival benefit over supportive care.
- Previous studies yielded mixed results, with some randomized trials showing no survival advantage.
Key Insights:
- Two recent high-quality randomized trials published in Hepatology and Lancet address the efficacy of TACE.
- These trials aim to resolve the long-standing debate on TACE's impact on patient survival.
- Findings are expected to establish the definitive role of TACE in palliative care for HCC.
Outlook:
- Clarification of TACE's role will guide clinical practice for unresectable HCC.
- Potential for improved patient management and outcomes.
- Further research may explore optimizing TACE or alternative palliative strategies.